Home › Blog › Cardiology › AI in Cardiology

Quick Answer

Cardiology is the stress test for medical AI because its evidence base moves faster than any model's training data. ESC Congress 2025 alone replaced or updated four major guidelines in one week. An AI tool earns the label evidence-based in cardiology only if it passes six testable properties: citations that resolve, guideline versions that are current and dated, jurisdiction awareness (CSI and LAI alongside ESC and ACC/AHA for Indian practice), surfaced uncertainty, retrieval-grounded answers, and an auditable trail. Retrieval is the property that carries the others: a 2025 JAMIA meta-analysis found retrieval-augmented generation significantly improved LLM accuracy over baseline (pooled OR 1.35; 95 percent CI 1.19-1.53), and only a retrieval architecture can index a new ESC guideline the week it publishes.

Key Takeaways

• Guideline velocity is the defining constraint: valvular heart disease, myocarditis and pericarditis, cardiovascular disease in pregnancy, and dyslipidaemia guidance all changed at ESC 2025. Static-training models are structurally unable to keep pace.
• Jurisdiction is the second constraint: Western risk calculators embedded in model training underestimate South Asian risk (PCE missed a two-fold excess of observed events in UK Biobank, HR 2.03), and India now has its own lipid guidance (CSI 2024, LAI consensus IV) that generic models never surface.
• The six-property checklist from our evidence-based AI framework applies to cardiology with two properties under maximum load: version currency and jurisdiction awareness.
• Grounding is measured, not promised: pooled OR 1.35 for accuracy across 20 studies (JAMIA, 2025); 43 to 99 percent accuracy with guideline-as-context designs; hallucinations eliminated in a controlled radiology comparison.
• The cardiologist remains the decision-maker; decision support that cannot show its sources and versions is not supporting the decision, it is replacing it with an unverifiable one.

Why Cardiology Is the Hardest Case for Medical AI

Every specialty has guidelines. Cardiology has a guideline metabolism. The ESC alone maintains dozens of clinical practice guidelines on rolling revision, and the 2025 Madrid congress demonstrated the tempo: a revised ESC/EACTS valvular heart disease guideline replacing 2021 guidance, the first combined myocarditis and pericarditis guideline replacing a 2015 document, a rebuilt cardiovascular disease in pregnancy guideline replacing the 2018 version, and a focused dyslipidaemia update that changed the recommended risk algorithm itself, endorsing SCORE2 and SCORE2-OP (Eur Heart J, 2025). ACC/AHA runs its own parallel cycle. Add the trial cadence (every hotline session at every major congress can shift practice within months) and the half-life of an undated cardiology answer is shorter than in any other specialty this series covers.

For a static-training AI model this is not a quality problem, it is an architecture problem. No amount of scale lets a model trained in 2024 quote a guideline published in August 2025. The model will still answer, fluently, from the superseded version. In cardiology, fluent and stale is the dangerous combination.

Indian practice adds a second structural constraint. The risk tools woven through Western guidelines and through model training data were derived from cohorts that do not look like Indian patients, and the divergence is documented, directional, and clinically consequential.

The Six Properties Under Cardiology Load

Our framework article defines six testable properties of evidence-based medical AI. Cardiology puts two of them under maximum load and gives the other four sharp specialty-specific tests.

1. Citations resolve. Ask for the source of an anticoagulation recommendation and open the link. The base-model failure rate is quantified at 28.6 percent hallucinated references for GPT-4 (Chelli et al, JMIR, 2024). In a specialty where recommendations carry class and level-of-evidence labels, a fabricated citation is not a formatting error; it is a fabricated class of recommendation.

2. Versions are current and dated. Maximum load. The test takes one question: "What is the current ESC guidance on pericarditis, and what changed in the most recent revision?" A tool that does not answer "the 2025 combined myocarditis and pericarditis guideline, replacing the 2015 document" is answering from a superseded evidence base, and every subsequent answer inherits that vintage. Re-run this test after every congress season.

3. Jurisdiction awareness. Maximum load. Indian cardiology now has its own documentary layer: the CSI dyslipidemia guidelines (2024), built on ICMR-INDIAB epidemiology, recommending non-fasting lipid profiles and first screening at age 18; the Lipid Association of India consensus statements; and the access realities of PMJAY packages and Indian generic pricing for guideline-directed therapy. A tool serving Indian cardiologists must hold ESC, ACC/AHA, and the Indian layer simultaneously and label which jurisdiction each answer draws from. The risk-calculation case makes the stakes concrete: the Pooled Cohort Equations failed to capture a two-fold excess of observed atherosclerotic events in South Asians (UK Biobank, HR 2.03; 95 percent CI 1.86-2.22), and underestimated risk in low-risk South Asian categories in a large US cohort (4.9 percent observed versus 1.8 percent predicted). A generic model returning an unadjusted PCE estimate for an Indian 45-year-old is reproducing a known bias with a confident interface.

4. Uncertainty is surfaced. Cardiology carries live disagreements: ESC versus ACC/AHA differences in heart failure thresholds and lipid targets, evolving positions on revascularisation in stable disease, and Indian guidance that deliberately departs from both. An evidence tool should present the disagreement, dated and attributed, not average it into a single confident sentence.

5. Answers are retrieval-grounded. The load-bearing property, and in cardiology the only one that survives the revision tempo. A retrieval system indexes the 2025 valvular guideline the week it publishes and answers from it the same week. The measured effect of grounding is consistent: pooled OR 1.35 for accuracy (JAMIA, 2025); 43 to 99 percent accuracy when guidelines were supplied as structured context in a hepatology framework study; hallucinations eliminated (8 percent to zero) in a controlled radiology comparison.

6. The trail is auditable. Heart teams, cath lab committees, and medicolegal review all require reconstructing why a recommendation was made. Question, sources retrieved, versions, synthesis: if that trail does not exist, the tool cannot participate in institutional decision-making, whatever its accuracy.

The Cardiology Stress Test

From ESC 2025 to the Indian Bedside: Three Working Scenarios

A cardiologist in Coimbatore is revising the hospital's valve clinic pathway after ESC 2025. The evidence question spans the new ESC/EACTS document, what changed from 2021, intervention thresholds, and which recommendations assume heart team infrastructure the hospital must formalise. Decision support here means the 2025 document, differenced against 2021, with citations, in minutes.

A physician in a Tier 3 town is deciding on primary prevention for a 42-year-old with a family history of premature CAD. The correct evidence surface includes the documented underestimation of South Asian risk by Western calculators, the CSI 2024 recommendation architecture, and non-fasting lipid interpretation. A generic chatbot returns a pooled-cohort number; an evidence platform should return the Indian context that changes the decision.

A DM resident preparing a journal club on the dyslipidaemia focused update needs what changed, why, and the trial base (the update drew on CLEAR Outcomes and SCORE2 validation work among others), with resolvable references. This is retrieval and synthesis, exactly the task the architecture exists for.

OneRX, an AI clinical decision support platform for doctors, is built against the six properties with cardiology's two maximum-load properties treated as design constraints: guideline indexing on publication, versions and dates on every answer, and CSI, LAI, and ICMR sources held alongside ESC and ACC/AHA with jurisdiction labelled. The claim is not infallibility; it is checkability. Run the stress-test table above against OneRX and against every alternative, and keep whichever tools pass.

How to Evaluate Any Cardiology AI Tool This Quarter

• Ask the pericarditis version question. Failure here is disqualifying, because it recurs at every revision cycle.
• Ask the Indian lipid question. A tool that never mentions CSI 2024 is not built for Indian practice.
• Open three citations. One fabricated reference disqualifies on the spot.
• Re-test after the next ESC and ACC congress seasons; currency is a property that decays.

Frequently Asked Questions

What is AI clinical decision support in cardiology?

Software that retrieves, synthesises, and presents current cardiology evidence (guidelines, trials, drug information) to support clinician decisions at the point of care. It is distinct from diagnostic AI such as ECG or imaging classifiers, and from general chatbots, which generate answers from static training data.

How is a decision-support platform different from ChatGPT for cardiology questions?

Architecture. General chatbots answer from parametric memory frozen at training time, which is why they quote superseded ESC guidance and fabricate references at documented rates. Retrieval-grounded platforms answer from an indexed, versioned corpus that can absorb a new guideline the week it publishes, with citations that resolve.

Why do AI risk estimates misread Indian patients?

Because the calculators in Western guidance and training data (Framingham, Pooled Cohort Equations) were derived from predominantly White cohorts. The PCE failed to capture a two-fold excess of observed events in South Asians in UK Biobank and underestimated risk in low-risk categories of a large US South Asian cohort. Indian guidance and recalibrated approaches address this; generic models rarely surface them.

Which Indian sources should a cardiology evidence platform index?

At minimum: CSI clinical practice guidelines (including the 2024 dyslipidemia guidelines), Lipid Association of India consensus statements, ICMR positions and INDIAB epidemiology, CDSCO approval status for cardiovascular drugs and devices, and PMJAY package context, alongside ESC, ACC/AHA, and the trial literature.

Can retrieval-grounded AI keep up with ESC guideline revisions?

That is precisely what the architecture is for. Indexing a published guideline is an ingestion task measured in days; retraining a foundation model is measured in months and cannot be triggered per document. The 2025 revision cycle is the clearest demonstration of why static models structurally cannot stay current in cardiology.

Conclusion

Cardiology sets the terms for what medical AI must be: current enough to survive a specialty that revised four major guidelines in one congress week, and jurisdiction-aware enough to serve a population that Western risk tools demonstrably misread. The six-property checklist turns those demands into ten-minute tests any cardiologist can run: dated versions, resolving citations, Indian sources surfaced, disagreements shown, retrieval named, trail auditable. Tools that pass deserve a place in the workflow. Tools that fail the version test in a specialty moving this fast will fail it again at every congress, and the answers in between will sound exactly as confident as the correct ones.